Literature DB >> 21277106

Patient preferences and physician practice patterns regarding breast radiotherapy.

David J Hoopes1, David Kaziska, Patrick Chapin, Daniel Weed, Benjamin D Smith, E Ronald Hale, Peter A Johnstone.   

Abstract

PURPOSE: There are multiple current strategies for breast radiotherapy (RT). The alignment of physician practice patterns with best evidence and patient preferences will enhance patient autonomy and improve cancer care. However, there is little information describing patient preferences for breast RT and physician practice patterns. METHODS AND MATERIALS: Using a reliable and valid instrument, we assessed the preferences of 5,000 randomly selected women (with or without cancer) undergoing mammography. To assess practice patterns, 2,150 randomly selected physician-members of American Society for Radiation Oncology were surveyed.
RESULTS: A total of 1,807 women (36%) and 363 physicians (17%) provided usable responses. The 95% confidence interval is < ± 2.3% for patients and < ± 5.3% for physicians. Patient preferences were hypofractionated whole breast irradiation (HF-WBI) 62%, partial breast irradiation (PBI) 28%, and conventionally fractionated whole breast irradiation (CF-WBI) 10%. By comparison, 82% of physicians use CF-WBI for more than 2/3 of women and 56% never use HF-WBI. With respect to PBI, 62% of women preferred three-dimensional (3D)-PBI and 38% favor brachytherapy-PBI, whereas 36% of physicians offer 3D-PBI and 66% offer brachytherapy-PBI. 70% of women prefer once-daily RT over 10 days vs. twice-daily RT over 5 days. 55% of physicians who use PBI do not offer PBI on clinical trial.
CONCLUSIONS: HF-WBI, while preferred by patients and supported by evidence, falls behind the unproven and less preferred strategy of PBI in clinical practice. There is a discrepancy between women's preferences for PBI modality and type of PBI offered by physicians. Further alignment is needed between practice patterns, patient preferences, and clinical evidence. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21277106     DOI: 10.1016/j.ijrobp.2010.11.077

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

1.  A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma.

Authors:  Anusha Kalbasi; Mitchell Kamrava; Fang-I Chu; Donatello Telesca; Ritchell Van Dams; Yingli Yang; Dan Ruan; Scott D Nelson; Sarah M Dry; Jackie Hernandez; Bartosz Chmielowski; Arun S Singh; Susan V Bukata; Nicholas M Bernthal; Michael L Steinberg; Joanne B Weidhaas; Fritz C Eilber
Journal:  Clin Cancer Res       Date:  2020-02-13       Impact factor: 12.531

2.  How should family physicians provide physical activity advice? Qualitative study to inform the design of an e-health intervention.

Authors:  Lindsay Reddeman; Nicole Bourgeois; Emily Nicholas Angl; Mike Heinrich; Leah Hillier; Holly Finn; Beth Bosiak; Payal Agarwal; Robin Mawson; Roni Propp; Noah M Ivers
Journal:  Can Fam Physician       Date:  2019-09       Impact factor: 3.275

3.  Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.

Authors:  Frank A Vicini; Reena S Cecchini; Julia R White; Douglas W Arthur; Thomas B Julian; Rachel A Rabinovitch; Robert R Kuske; Patricia A Ganz; David S Parda; Michael F Scheier; Kathryn A Winter; Soonmyung Paik; Henry M Kuerer; Laura A Vallow; Lori J Pierce; Eleftherios P Mamounas; Beryl McCormick; Joseph P Costantino; Harry D Bear; Isabelle Germain; Gregory Gustafson; Linda Grossheim; Ivy A Petersen; Richard S Hudes; Walter J Curran; John L Bryant; Norman Wolmark
Journal:  Lancet       Date:  2019-12-05       Impact factor: 79.321

4.  Association of Utilization Management Policy With Uptake of Hypofractionated Radiotherapy Among Patients With Early-Stage Breast Cancer.

Authors:  Ravi B Parikh; Ezra Fishman; Winnie Chi; Robert P Zimmerman; Atul Gupta; John J Barron; Gosia Sylwestrzak; Justin E Bekelman
Journal:  JAMA Oncol       Date:  2020-06-01       Impact factor: 31.777

5.  Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008-2013.

Authors:  Justin E Bekelman; Gosia Sylwestrzak; John Barron; Jinan Liu; Andrew J Epstein; Gary Freedman; Jennifer Malin; Ezekiel J Emanuel
Journal:  JAMA       Date:  2014-12-17       Impact factor: 56.272

6.  Breast Cancer Patients' Preferences for Adjuvant Radiotherapy Post Lumpectomy: Whole Breast Irradiation vs. Partial Breast Irradiation-Single Institutional Study.

Authors:  Katija Bonin; Merrylee McGuffin; Roseanna Presutti; Tamara Harth; Aruz Mesci; Deb Feldman-Stewart; Edward Chow; Lisa Di Prospero; Danny Vesprini; Eileen Rakovitch; Justin Lee; Lawrence Paszat; Mary Doherty; Hany Soliman; Ida Ackerman; Xingshan Cao; Alex Kiss; Ewa Szumacher
Journal:  J Cancer Educ       Date:  2018-02       Impact factor: 2.037

7.  Getting the next version of payment policy "right" on the road toward accountable cancer care.

Authors:  Justin E Bekelman; Andrew J Epstein; Ezekiel J Emanuel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-08       Impact factor: 7.038

8.  Comparison of Mammographic Changes Across Three Different Fractionation Schedules for Early-Stage Breast Cancer.

Authors:  Sibo Tian; Lina F Paster; Sinae Kim; Laurie Kirstein; Bruce G Haffty; Adam Ferro; Judith Amorosa; Sharad Goyal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-04       Impact factor: 7.038

9.  The case for radiotherapy in a Value based environment.

Authors:  Peter A S Johnstone; Susan Peneguy; Timothy N Showalter; James B Yu
Journal:  Rep Pract Oncol Radiother       Date:  2019-02-20

10.  Physician trajectories of abandoning long-course breast radiotherapy and their cost impact.

Authors:  Xiao Xu; Pamela R Soulos; Jeph Herrin; Shi-Yi Wang; Craig Evan Pollack; Suzanne B Evans; James B Yu; Cary P Gross
Journal:  Health Serv Res       Date:  2020-10-18       Impact factor: 3.734

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.